A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of Ibat Inhibition With Multidose Measurement for Evaluation of Response)

Trial Profile

A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of Ibat Inhibition With Multidose Measurement for Evaluation of Response)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs GSK 2330672 (Primary)
  • Indications Cholestasis; Primary biliary cirrhosis
  • Focus Therapeutic Use
  • Acronyms GLIMMER
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Sep 2017 Planned End Date changed from 23 Apr 2018 to 9 Aug 2019.
    • 07 Sep 2017 Planned primary completion date changed from 23 Apr 2018 to 9 Aug 2019.
    • 20 Jan 2017 Planned End Date changed from 1 May 2018 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top